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Acute and EongTerm Bela-Adrenergic 
Bfochde for lwerrats with 
~~~~a~jo~~~j~ syncope 
We cr$yd the study hy Cox ct al, (1) on betaFdrenergic blockade 
therapy fx ne~urocardiogcnic syncope. This study attempted to show 
that patients; who presented with syncopr and near syncopt: had 
significantly fewer episodes of recurrent syncope and near syncope in 
12 months of follow-up if the baseline Lhnormal tilt tahlr study result 
normalixd on a repeat study usmg beta-bl&cr therapy. We had 
severa c+mcerns with the study: 
Tlr first ctrnccrn was the tilt tahlc proton)4 used. hforc spxifieally, 
wc wmdeted whether the investigators had asscsscd what their ft!lse 
p0siitivB rate c)f till studies was in normal subjects, given the r&tivC4~ 
short (ii) min) bwrline study folloucd by an :rgrcssive isoprotcrcnol 
infusinn protowi. This is imprunt bcxause isnprokrunol has been 
:issrX:ialcd with an increaod t&c positive ralt: (2). Secctnd was the: 
atrsencc of a pla~cbo arm. which we think was rthica4 in view of the 
benign prognosis that these patients have. This issue has obvious 
rlinical impiications regarding the need fi?r long-term therapy. Third. 
the inclusion of patients with near qncope was yuestionablc becaux it 
was ncvcr defined and may repre.sent a “soft” end point that would he 
dif4icdlt to measure. it would be interesting to see whether therapy still 
;q+;rrcd tn crntr some clinical benefit if only patients with recurrent 
sy~rcope were analyzed and unly recurrences d syncopo #were accept- 
at& end points. The stated benefit of therapy for this scenario would 
he unlikci; because 39.8% of patients had either near syncop~ or one 
cpisodc of sytxt~p~. Finally, the duration of foftclw-up relative to ~hc 
rrreqticncy of ieported cpisudes appzarcd truncated. More specifically, 
a D-month foliow-up period would be inadequate in many of these 
patients because their event rate was not stated to be at least two 
episode@ar without therapy. If most of the patients had episodes of 
yncqx years alrart, a IOII~IX follow-up period would br needed, and 
the :Ihilily to prove drug c%c:q wcxdd hc problematic, 
In sutnmiu’y. although we think that C~X et al. (I) had a clinically 
rcluvant hypothesis to test, the study design flaws noted hex make the 
stildy rwdts and conclusions difiisult to xccpt. 
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R&V 
Ic :;~NISC IO the comments aud questions S$ V&h and IIcAutonio, 
WC did not estimate the hlsc: positive rate in normal subjects with our 
pr?Xcxol. I$we~er, we followed the protocol of Almquist et al. (I), 
<which revetiicd tin 11% false positive rate. The mean age of their 
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